| Literature DB >> 15992675 |
T Miko Enomoto1, Per Thorborg.
Abstract
Recombinant activated factor VII (rFVIIa) is currently licensed in the United States for treatment of bleeding episodes in patients with deficiencies of factor VIII (FVIII) or IX (FIX) who are refractory to factor replacement because of circulating inhibitors. A 1999 report of its successful use to stop what was deemed to be lethal hemorrhage after an abdominal gunshot wound in a young soldier without pre-existing coagulopathy has prompted exploration of other uses for rFVIIa. The virtual explosion of proposed uses of rFVIIa raises issues not only regarding our understanding of the coagulation system, but also regarding its efficacy, cost-effectiveness, and safety.Entities:
Mesh：
Substances：
Year: 2005 PMID： 15992675 DOI： 10.1016/j.ccc.2005.04.001
Source DB: PubMed Journal: Crit Care Clin ISSN： 0749-0704 Impact factor: 3.598